Design Therapeutics (NASDAQ:DSGN) Trading Up 1.3% – Time to Buy?

Design Therapeutics, Inc. (NASDAQ:DSGN) was up 1.3% during trading on Monday . The company traded as high as $5.60 and last traded at $5.40. Approximately 154,551 shares traded hands during trading, an increase of 33% from the average daily volume of 116,630 shares. The stock had previously closed at $5.33.

Design Therapeutics Trading Up 1.3%

The firm has a market cap of $307.53 million, a PE ratio of -4.82 and a beta of 1.58. The business’s 50-day simple moving average is $4.07 and its 200 day simple moving average is $4.08.

Design Therapeutics (NASDAQ:DSGN) last released its quarterly earnings results on Thursday, August 7th. The company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.02). Analysts expect that Design Therapeutics, Inc. will post -0.91 earnings per share for the current year.

Institutional Trading of Design Therapeutics

A number of institutional investors have recently modified their holdings of DSGN. Los Angeles Capital Management LLC acquired a new stake in Design Therapeutics in the 2nd quarter worth approximately $43,000. Invesco Ltd. lifted its stake in Design Therapeutics by 26.8% during the 2nd quarter. Invesco Ltd. now owns 14,364 shares of the company’s stock valued at $48,000 after acquiring an additional 3,033 shares during the period. Velan Capital Investment Management LP acquired a new stake in Design Therapeutics during the 1st quarter valued at approximately $54,000. Jane Street Group LLC acquired a new stake in Design Therapeutics during the 1st quarter valued at approximately $70,000. Finally, ProShare Advisors LLC acquired a new stake in Design Therapeutics during the 4th quarter valued at approximately $71,000. 56.64% of the stock is currently owned by institutional investors.

Design Therapeutics Company Profile

Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.